Literature DB >> 73408

Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay.

A Broughton, J E Strong, P Y Holoye, C W Bedrossian.   

Abstract

The clinical pharmacology of bleomycin administered by continuous intravenous infusion over a 4 to 5 day period was examined by nine patients. Patients receiving 30 units per day attained an average steady state plasma level of 145.8 (+/- 43.1) ng/ml bleomycin. Elimination of bleomycin was initially described by first order rate kinetics (t 1/2 = 1.32 +/- 0.39 hour). However, at times greater than 12 hours following termination of infusion, a second elimination phase was observed (t 1/2 = 8.9 +/- 2.7 hour). There was also a high correlation between renal bleomycin clearance and creatinine clearance. The importance of renal clearance was indicated in a patient with renal impairment. This patient attained a steady state bleomycin concentration of 1046 ng/ml and exhibited a terminal elimination half-life of 33 hours. Overall plasma clearance of bleomycin (Qbeta) was generally greater than renal clearance, indicating that a nonrenal clearance mechanism was also important in bleomycin elimination. This nonrenal mechanism became especially apparent during renal failure.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 73408     DOI: 10.1002/1097-0142(197712)40:6<2772::aid-cncr2820400603>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Augmentation of fibroblast proliferation by bleomycin.

Authors:  P L Moseley; C Hemken; G W Hunninghake
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

Review 2.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

4.  A pharmacokinetic evaluation of IM administration of bleomycin oil suspension.

Authors:  M Davy; E Paus; G Lehne
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Combination chemotherapy in malignant non-seminomatous germ-cell tumors: results of a cooperative study of the German Society of Pediatric Oncology (MAKEI 83).

Authors:  U Gobel; G Calaminus; R J Häas; H Jurgens; D Niethammer; J Ritter; H J Spaar; D Harms
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P.

Authors:  Darrell Pilling; David Roife; Min Wang; Sanna D Ronkainen; Jeff R Crawford; Elizabeth L Travis; Richard H Gomer
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

8.  Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.

Authors:  Laszlo Markasz; György Stuber; Emilie Flaberg; Asa Gustafsson Jernberg; Staffan Eksborg; Eva Olah; Henriette Skribek; Laszlo Szekely
Journal:  BMC Cancer       Date:  2006-11-13       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.